Bristol Myers Squibb (BMY) Gross Margin (2009 - 2026)

Bristol Myers Squibb has disclosed Gross Margin across 18 years of filings, most recently posting 70.22% for Q1 2026.

• In Q1 2026, Gross Margin fell 270.0% year-over-year to 70.22%; the TTM figure through Mar 2026 stood at 70.45% (down 1.0% YoY), while the FY2025 annual figure was 71.08%, changed 0.0% from the prior year.
• Gross Margin rose to 70.22% in Q1 2026, from 67.23% in the prior quarter.
• Over the last five years, Gross Margin for BMY reached as high as 79.02% in Q3 2022 and fell as low as 61.01% in Q4 2024.
• The 5-year median for Gross Margin is 75.13% (2024), against an average of 73.92%.
• Annual changes were most pronounced in 2024 — Gross Margin slumped 1507 bps — and 2025, when it surged 622 bps.
• A 5-year view of Gross Margin shows it stood at 77.27% in 2022, then slipped by 2 bps to 76.08% in 2023, then retreated by 20 bps to 61.01% in 2024, then advanced by 10 bps to 67.23% in 2025, then grew by 4 bps to 70.22% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 70.22%, 67.23%, and 71.89% for Q1 2026, Q4 2025, and Q3 2025 respectively.